The aromatic ketone 4′-hydroxychalcone inhibits TNFα-induced NF-κB activation via proteasome inhibition

Biochemical Pharmacology

Volumn 82, Issue 6, 2011, Pages 620-631

  Orlikova, Barbora ^a   Tasdemir, Deniz ^b   Golais, Frantisek ^c   Dicato, Mario ^a   Diederich, Marc ^a  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c Physics and Informatics   (Slovakia)

Author keywords

Cancer; Chalcone; Inflammation; NF B; Polyphenol

Indexed keywords

4' HYDROXYCHALCONE; ANTINEOPLASTIC AGENT; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KETONE DERIVATIVE; PROTEASOME; PROTEIN P50; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CHALCONES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMANS; I-KAPPA B KINASE; LEUKOCYTES, MONONUCLEAR; LUCIFERASES; MOLECULAR STRUCTURE; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051549637     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.06.012     Document Type: Article

References (54)

1. Y.L. Hsu, P.L. Kuo, W.S. Tzeng, and C.C. Lin Chalcone inhibits the proliferation of human breast cancer cell by blocking cell cycle progression and inducing apoptosis Food Chem Toxicol 44 2006 704 713
2. J. Loa, P. Chow, and K. Zhang Studies of structure-activity relationship on plant polyphenol-induced suppression of human liver cancer cells Cancer Chemother Pharmacol 63 2009 1007 1016
3. M. Cabrera, M. Simoens, G. Falchi, M.L. Lavaggi, O.E. Piro, and E.E. Castellano Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships Bioorg Med Chem 15 2007 3356 3367 (Pubitemid 46529269)
4. R. De Vincenzo, G. Scambia, P. Benedetti Panici, F.O. Ranelletti, G. Bonanno, and A. Ercoli Effect of synthetic and naturally occurring chalcones on ovarian cancer cell growth: structure-activity relationships Anticancer Drug Des 10 1995 481 490
5. K.S. Ahn, G. Sethi, and B.B. Aggarwal Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway Biochem Pharmacol 75 2008 907 913 (Pubitemid 351174113)
6. R.C. Bargou, F. Emmerich, D. Krappmann, K. Bommert, M.Y. Mapara, and W. Arnold Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells J Clin Invest 100 1997 2961 2969 (Pubitemid 28022832)
7. A. Cadoret, F. Bertrand, S. Baron-Delage, P. Levy, G. Courtois, and C. Gespach Down-regulation of NF-kappaB activity and NF-kappaB p65 subunit expression by ras and polyoma middle T oncogenes in human colonic Caco-2 cells Oncogene 14 1997 1589 1600 (Pubitemid 27182842)
8. H. Nakshatri, P. Bhat-Nakshatri, D.A. Martin, R.J. Goulet Jr. , and G.W. Sledge Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth Mol Cell Biol 17 1997 3629 3639 (Pubitemid 27281838)
9. R.L. Shattuck-Brandt, and A. Richmond Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells Cancer Res 57 1997 3032 3039 (Pubitemid 27315057)
10. M.A. Sovak, R.E. Bellas, D.W. Kim, G.J. Zanieski, A.E. Rogers, and A.M. Traish Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer J Clin Invest 100 1997 2952 2960 (Pubitemid 28022831)
11. C.H. Lee, Y.T. Jeon, S.H. Kim, and Y.S. Song NF-kappaB as a potential molecular target for cancer therapy Biofactors 29 2007 19 35 (Pubitemid 46985299)
12. Y.L. Pobezinskaya, Y.S. Kim, S. Choksi, M.J. Morgan, T. Li, and C. Liu The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors Nat Immunol 9 2008 1047 1054
13. A. Duvoix, S. Delhalle, R. Blasius, M. Schnekenburger, F. Morceau, and M. Fougere Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappaB inhibition Biochem Pharmacol 68 2004 1101 1111 (Pubitemid 39094274)
14. G. Takaesu, R.M. Surabhi, K.J. Park, J. Ninomiya-Tsuji, K. Matsumoto, and R.B. Gaynor TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway J Mol Biol 326 2003 105 115 (Pubitemid 36279361)
15. A. van de Stolpe, E. Caldenhoven, B.G. Stade, L. Koenderman, J.A. Raaijmakers, and J.P. Johnson 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter J Biol Chem 269 1994 6185 6192
16. S. Hirai, Y.I. Kim, T. Goto, M.S. Kang, M. Yoshimura, and A. Obata Inhibitory effect of naringenin chalcone on inflammatory changes in the interaction between adipocytes and macrophages Life Sci 81 2007 1272 1279 (Pubitemid 47539506)
17. J.Y. Kim, S.J. Park, K.J. Yun, Y.W. Cho, H.J. Park, and K.T. Lee Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages Eur J Pharmacol 584 2008 175 184
18. S. Kumar, A. Sharma, B. Madan, V. Singhal, and B. Ghosh Isoliquiritigenin inhibits IkappaB kinase activity and ROS generation to block TNF-alpha induced expression of cell adhesion molecules on human endothelial cells Biochem Pharmacol 73 2007 1602 1612 (Pubitemid 46533973)
19. H.M. Kwon, Y.J. Choi, J.S. Choi, S.W. Kang, J.Y. Bae, and I.J. Kang Blockade of cytokine-induced endothelial cell adhesion molecule expression by licorice isoliquiritigenin through NF-kappaB signal disruption Exp Biol Med (Maywood) 232 2007 235 245
20. M.K. Pandey, S.K. Sandur, B. Sung, G. Sethi, A.B. Kunnumakkara, and B.B. Aggarwal Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue J Biol Chem 282 2007 17340 17350 (Pubitemid 47100316)
21. B. Srinivasan, T.E. Johnson, R. Lad, and C. Xing Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3′,4′, 5′-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities J Med Chem 52 2009 7228 7235
22. V.R. Yadav, S. Prasad, B. Sung, and B.B. Aggarwal The role of chalcones in suppression of NF-kappaB-mediated inflammation and cancer Int Immunopharmacol 11 2011 295 309
23. S.J. Corey, M.D. Minden, D.L. Barber, H. Kantarjian, J.C. Wang, and A.D. Schimmer Myelodysplastic syndromes: the complexity of stem-cell diseases Nat Rev Cancer 7 2007 118 129 (Pubitemid 46164747)
24. H. Hacker, and M. Karin Regulation and function of IKK and IKK-related kinases Sci STKE 2006 2006 re13
25. M. Karin, and Y. Ben-Neriah Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity Annu Rev Immunol 18 2000 621 663 (Pubitemid 30365393)
26. H. Hsu, H.B. Shu, M.G. Pan, and D.V. Goeddel TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways Cell 84 1996 299 308 (Pubitemid 26042835)
27. M.J. Bertrand, S. Milutinovic, K.M. Dickson, W.C. Ho, A. Boudreault, and J. Durkin cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination Mol Cell 30 2008 689 700 (Pubitemid 351818251)
28. S.M. Park, J.B. Yoon, and T.H. Lee Receptor interacting protein is ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in vitro FEBS Lett 566 2004 151 156 (Pubitemid 38625950)
29. A. Kanayama, R.B. Seth, L. Sun, C.K. Ea, M. Hong, and A. Shaito TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains Mol Cell 15 2004 535 548 (Pubitemid 39141781)
30. P.C. Cheung, A.R. Nebreda, and P. Cohen TAB3, a new binding partner of the protein kinase TAK1 Biochem J 378 2004 27 34 (Pubitemid 38299541)
31. T. Ishitani, G. Takaesu, J. Ninomiya-Tsuji, H. Shibuya, R.B. Gaynor, and K. Matsumoto Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling EMBO J 22 2003 6277 6288 (Pubitemid 37522585)
32. G. Takaesu, S. Kishida, A. Hiyama, K. Yamaguchi, H. Shibuya, and K. Irie TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway Mol Cell 5 2000 649 658
33. H. Sakurai, H. Miyoshi, W. Toriumi, and T. Sugita Functional interactions of transforming growth factor beta-activated kinase 1 with IkappaB kinases to stimulate NF-kappaB activation J Biol Chem 274 1999 10641 10648
34. J. George, N.L. Banik, and S.K. Ray Genistein induces receptor and mitochondrial pathways and increases apoptosis during BCL-2 knockdown in human malignant neuroblastoma SK-N-DZ cells J Neurosci Res 88 2010 877 886
35. L.Y. Shiu, L.C. Chang, C.H. Liang, Y.S. Huang, H.M. Sheu, and K.W. Kuo Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin Food Chem Toxicol 45 2007 2155 2164 [An International Journal Published for the British Industrial Biological Research Association] (Pubitemid 47451570)
36. V. Tergaonkar NFkappaB pathway: a good signaling paradigm and therapeutic target Int J Biochem Cell Biol 38 2006 1647 1653 (Pubitemid 43947652)
37. F. Balkwill Tumour necrosis factor and cancer Nat Rev Cancer 9 2009 361 371
38. G. Sethi, B. Sung, and B.B. Aggarwal TNF: a master switch for inflammation to cancer Front Biosci 13 2008 5094 5107 (Pubitemid 351599660)
39. L. Kozlowski, I. Zakrzewska, P. Tokajuk, and M.Z. Wojtukiewicz Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients Rocz Akad Med Bialymst 48 2003 82 84
40. I.H. Benoy, R. Salgado, P. Van Dam, K. Geboers, E. Van Marck, and S. Scharpe Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival Clin Cancer Res 10 2004 7157 7162 (Pubitemid 39487700)
41. A.J. Lambeck, A.P. Crijns, N. Leffers, W.J. Sluiter, K.A. ten Hoor, and M. Braid Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7 Clin Cancer Res 13 2007 2385 2391 (Pubitemid 46698588)
42. A.E. Lokshin, M. Winans, D. Landsittel, A.M. Marrangoni, L. Velikokhatnaya, and F. Modugno Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer Gynecol Oncol 102 2006 244 251 (Pubitemid 44041638)
43. S. Lehrer, E.J. Diamond, B. Mamkine, N.N. Stone, and R.G. Stock Serum interleukin-8 is elevated in men with prostate cancer and bone metastases Technol Cancer Res Treat 3 2004 411 (Pubitemid 39391995)
44. J. Pfitzenmaier, R. Vessella, C.S. Higano, J.L. Noteboom, D. Wallace Jr. , and E. Corey Elevation of cytokine levels in cachectic patients with prostate carcinoma Cancer 97 2003 1211 1216 (Pubitemid 36237306)
45. F. Tas, D. Duranyildiz, H. Oguz, H. Camlica, V. Yasasever, and E. Topuz Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer Cancer Invest 24 2006 492 496 (Pubitemid 44576401)
46. S.J. Wigmore, K.C. Fearon, K. Sangster, J.P. Maingay, O.J. Garden, and J.A. Ross Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer Int J Oncol 21 2002 881 886
47. S. Brennecke, M. Deichmann, H. Naeher, and H. Kurzen Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma Melanoma Res 15 2005 515 522 (Pubitemid 44124263)
48. S. Huang, L. Mills, B. Mian, C. Tellez, M. McCarty, and X.D. Yang Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma Am J Pathol 161 2002 125 134 (Pubitemid 34760778)
49. B.M. Mian, C.P. Dinney, C.E. Bermejo, P. Sweeney, C. Tellez, and X.D. Yang Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB Clin Cancer Res 9 2003 3167 3175 (Pubitemid 36993279)
50. W.M. Merritt, Y.G. Lin, W.A. Spannuth, M.S. Fletcher, A.A. Kamat, and L.Y. Han Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth J Natl Cancer Inst 100 2008 359 372 (Pubitemid 351480526)
51. D.J. Brat, A.C. Bellail, and E.G. Van Meir The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis Neuro Oncol 7 2005 122 133 (Pubitemid 40590513)
52. B.B. Ancrile, K.M. O'Hayer, and C.M. Counter Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics Mol Interv 8 2008 22 27 (Pubitemid 351398449)
53. A. De Luca, A. Carotenuto, A. Rachiglio, M. Gallo, M.R. Maiello, and D. Aldinucci The role of the EGFR signaling in tumor microenvironment J Cell Physiol 214 2008 559 567 (Pubitemid 351224199)
54. Y. Lin, L. Bai, W. Chen, and S. Xu The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy Expert Opin Ther Targets 14 2010 45 55